Charles Swanton

109.3k total citations · 23 hit papers
325 papers, 30.6k citations indexed

About

Charles Swanton is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Charles Swanton has authored 325 papers receiving a total of 30.6k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Cancer Research, 145 papers in Oncology and 132 papers in Molecular Biology. Recurrent topics in Charles Swanton's work include Cancer Genomics and Diagnostics (166 papers), Lung Cancer Treatments and Mutations (49 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Charles Swanton is often cited by papers focused on Cancer Genomics and Diagnostics (166 papers), Lung Cancer Treatments and Mutations (49 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Charles Swanton collaborates with scholars based in United Kingdom, United States and Denmark. Charles Swanton's co-authors include Nicholas McGranahan, Rebecca A. Burrell, Samra Turajlic, Jiří Bártek, Nicolai J. Birkbak, Sergio A. Quezada, Lajos Pusztai, Marco Gerlinger, James Larkin and Solange Peters and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Charles Swanton

312 papers receiving 30.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

2018 1.8k citations Charles Swanton, Sergio A. Quezada et al. Annals of Oncology profile →
Renal cell carcinoma

2017 1.8k citations Charles Swanton et al. profile →
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

2017 1.8k citations Nicholas McGranahan, Charles Swanton Cell profile →
The causes and consequences of genetic heterogeneity in cancer evolution

2013 1.6k citations Rebecca A. Burrell, Nicholas McGranahan et al. profile →
Artificial intelligence in cancer imaging: Clinical challenges and applications

2019 1.2k citations Nicolai J. Birkbak, Charles Swanton et al. profile →
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

2015 765 citations Nicholas McGranahan, Charles Swanton profile →
Cancer heterogeneity: implications for targeted therapeutics

2013 717 citations Charles Swanton et al. profile →
Intratumor Heterogeneity: Evolution through Space and Time

2012 672 citations Charles Swanton Cancer Research profile →
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

2017 662 citations Rachel Rosenthal, Nicholas McGranahan et al. profile →
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution

2016 630 citations Rachel Rosenthal, Nicholas McGranahan et al. profile →
Genetic prognostic and predictive markers in colorectal cancer

2009 529 citations Axel Walther, Charles Swanton et al. profile →
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

2021 520 citations Charles Swanton et al. Annals of Oncology profile →
Metastasis as an evolutionary process

2016 462 citations Charles Swanton et al. profile →
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

2015 432 citations Nicholas McGranahan, Nicolai J. Birkbak et al. profile →
Clinical management of breast cancer heterogeneity

2015 426 citations Charles Swanton et al. profile →
Resolving genetic heterogeneity in cancer

2019 407 citations Charles Swanton et al. profile →
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

2018 391 citations Charlotte K.Y. Ng, Charles Swanton et al. Annals of Oncology profile →
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

2019 383 citations Funda Meric‐Bernstam, Herbert I. Hurwitz et al. profile →
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

2019 372 citations Nicolai J. Birkbak, Charles Swanton et al. Annals of Oncology profile →
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology profile →
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

2021 251 citations Razelle Kurzrock, John D. Hainsworth et al. profile →
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

2024 235 citations Maise Al Bakir, Charles Swanton et al. Cell profile →
Why do patients with cancer die?

2024 43 citations Mariam Jamal‐Hanjani, Charles Swanton et al. profile →

Peers

Countries citing papers authored by Charles Swanton

Since Specialization

Citations

This map shows the geographic impact of Charles Swanton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Swanton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Swanton more than expected).

Fields of papers citing papers by Charles Swanton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Swanton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Swanton. The network helps show where Charles Swanton may publish in the future.

Co-authorship network of co-authors of Charles Swanton

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Swanton. A scholar is included among the top collaborators of Charles Swanton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Swanton. Charles Swanton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extrachromosomal DNA: shaping the evolutionary dynamics of cancer 2025 ·Trends in cancer ·(unknown), Imran Noorani, Charles Swanton, Paul S. Mischel, Benjamin Werner	1
2	An agent-based modelling framework to study growth mechanisms in EGFR-L858R mutant cell alveolar type II cells 2024 ·Royal Society Open Science ·(unknown), Clare E. Weeden, Philip Pearce, (unknown), Alastair Magness, Charles Swanton, Karen M. Page	2
3	Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial. 2024 ·Journal of Clinical Oncology ·Mark Linch, Gianmarco Leone, Yien Ning Sophia Wong, Robert J. Jones, Peter Sankey, Debra H. Josephs, Simon J. Crabb, Louise Harris, Aniqa Tasnim, (unknown), Sergio A. Quezada, Leah Ensell, Anuradha Jayaram, (unknown), Colin C. Pritchard, Alex Freeman, Aiman Haider, Gerhardt Attard, Charles Swanton, Teresa Marafioti	5
4	LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer 2023 ·Annals of Oncology ·James R. Black, Alexander M. Frankell, Selvaraju Veeriah, (unknown), Mark S. Hill, Charles W. Abbott, (unknown), Bo Li, Rui Chen, Maise Al Bakir, (unknown), Ariana Huebner, Mariam Jamal‐Hanjani, Nicholas McGranahan, Charles Swanton	6
5	Impact of risk factors on early cancer evolution 2023 ·Cell ·Clare E. Weeden, William Hill, Emilia L. Lim, Eva Grönroos, Charles Swanton	61
6	RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma 2022 ·Nature Communications ·Philip East, Gavin Kelly, Dhruva Biswas, Michela Marani, David C. Hancock, Todd Creasy, Kris F. Sachsenmeier, Charles Swanton, Julian Downward, Sophie de Carné Trécesson	16
7	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study 2021 ·Cancer Discovery ·Claire F. Friedman, John D. Hainsworth, Razelle Kurzrock, David R. Spigel, Howard A. Burris, Christopher J. Sweeney, Funda Meric‐Bernstam, Yong Wang, Jonathan Levy, Jessica M. Grindheim, David S. Shames, Katja Schulze, Arisha Patel, Charles Swanton	56
8	APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution 2018 ·UCL Discovery (University College London) ·Subramanian Venkatesan, Rachel Rosenthal, Nnennaya Kanu, Nicholas McGranahan, (unknown), (unknown), J.D. Hare, (unknown), Charles Swanton	1
9	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study breakdown → 2018 ·Journal of Clinical Oncology ·John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock	357
10	APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability 2017 ·Cancer Discovery ·Laurent Sansregret, James O. Patterson, Sally M. Dewhurst, Carlos López‐García, André Koch, Nicholas McGranahan, William Chong Hang Chao, David J. Barry, Andrew Rowan, Rachael Instrell, Stuart Horswell, Michael Way, Michael Howell, Martin R. Singleton, René H. Medema, Paul Nurse, Mark Petronczki, Charles Swanton	80
11	Cellular Prion Protein PrPC and Ecto-5′-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy 2017 ·Cancer Research ·Patrícia H. Domingues, Lalitha S.Y. Nanduri, (unknown), (unknown), (unknown), Cristina Viganó, Conrad von Schubert, Erich A. Nigg, Charles Swanton, Rocı́o Sotillo, Andreas Bosio, Zuzana Štorchová, Olaf Hardt	8
12	Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy 2015 ·Cancer Discovery ·Nirupa Murugaesu, Gareth A. Wilson, Nicolai J. Birkbak, Thomas B.K. Watkins, Nicholas McGranahan, Sacheen Kumar, Nima Abbassi‐Ghadi, Max Salm, Richard Mitter, Stuart Horswell, Andrew Rowan, Benjamin Phillimore, Jennifer Biggs, Sharmin Begum, Nik Matthews, Daniel Hochhauser, George B. Hanna, Charles Swanton	178
13	Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance 2014 ·Cancer Research ·Charlotte K.Y. Ng, Britta Weigelt, Roger A’Hern, François‐Clément Bidard, Christophe Lemetre, Charles Swanton, Ronglai Shen, Jorge S. Reis‐Filho	15
14	Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution 2014 ·Cancer Discovery ·Sally M. Dewhurst, Nicholas McGranahan, Rebecca A. Burrell, Andrew J. Rowan, Eva Grönroos, David Endesfelder, Tejal Joshi, Dmitri Mouradov, Peter Gibbs, Robyn L. Ward, Nicholas J. Hawkins, Zoltán Szállási, Oliver M. Sieber, Charles Swanton	287
15	89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients 2014 ·Clinical Cancer Research ·Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen, Sue Chua, Thijs H. Oude Munnink, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Mikhail Akimov, (unknown), Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries, Charles Swanton, Udai Banerji	95
16	Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer 2014 ·Cancer Research ·David Endesfelder, Rebecca A. Burrell, Nnennaya Kanu, Nicholas McGranahan, Michael Howell, Peter J. Parker, Julian Downward, Charles Swanton, Maik Kschischo	47
17	Chromosomal Instability Confers Intrinsic Multidrug Resistance 2011 ·Cancer Research ·Alvin Lee, David Endesfelder, Andrew J. Rowan, Axel Walther, Nicolai J. Birkbak, P. Andrew Futreal, Julian Downward, Zoltán Szállási, Ian Tomlinson, Michael Howell, Maik Kschischo, Charles Swanton	358
18	Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer 2011 ·Cancer Research ·Nicolai J. Birkbak, Aron C. Eklund, Qiyuan Li, Sarah E. McClelland, David Endesfelder, Patrick Tan, Iain Beehuat Tan, Andrea L. Richardson, Zoltán Szállási, Charles Swanton	258
19	Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer 2011 ·Cancer Epidemiology Biomarkers & Prevention ·Rebecca Roylance, David Endesfelder, Patricia Gorman, Rebecca A. Burrell, Jil Sander, Ian Tomlinson, Andrew M. Hanby, Valerie Speirs, Andrea L. Richardson, Nicolai J. Birkbak, Aron C. Eklund, Julian Downward, Maik Kschischo, Zoltán Szállási, Charles Swanton	133
20	FKBPL Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy 2010 ·Cancer Research ·Hayley D. McKeen, Christopher Byrne, Puthen V. Jithesh, (unknown), Andrea Valentine, Anita Yakkundi, Martin O’Rourke, Charles Swanton, Helen O. McCarthy, David G. Hirst, Tracy Robson	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact